Maohuoside A
(Synonyms: 茂藿苷A) 目录号 : GC60239MaohuosideA,一种从E.koreanum中分离出的单一化合物,可有效促进成骨作用。MaohuosideA通过骨形态发生蛋白(BMP)和MAPK信号通路增强了骨髓间充质干细胞的成骨作用。
Cas No.:128988-55-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways[1][2].
[1]. Ming Cai, et al. Maohuoside A Acts in a BMP-dependent Manner During Osteogenesis. Phytother Res. 2013 Aug;27(8):1179-84. [2]. Lei Yang, et al. Maohuoside A Promotes Osteogenesis of Rat Mesenchymal Stem Cells via BMP and MAPK Signaling Pathways. Mol Cell Biochem. 2011 Dec;358(1-2):37-44.
Cas No. | 128988-55-6 | SDF | |
别名 | 茂藿苷A | ||
Canonical SMILES | O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(CCC(C)(O)C)C(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)=CC(O)=C13 | ||
分子式 | C27H32O12 | 分子量 | 548.54 |
溶解度 | 储存条件 | ||
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.823 mL | 9.1151 mL | 18.2302 mL |
5 mM | 0.3646 mL | 1.823 mL | 3.646 mL |
10 mM | 0.1823 mL | 0.9115 mL | 1.823 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Maohuoside A acts in a BMP-dependent manner during osteogenesis
Phytother Res 2013 Aug;27(8):1179-84.PMID:23007945DOI:10.1002/ptr.4840.
There has been a strong interest in searching for natural therapies for osteoporosis. Epimedium koreanum Nakai is an herb that is commonly used in East Asia to treat osteoporosis, and most studies of its activity have focused on its major ingredient, icariin. In this study, Maohuoside A (MHA), a single compound isolated from the E. koreanum, was found to promote osteogenesis in mouse bone marrow-derived mesenchymal stem cells. We hypothesise that, if MHA potently induces osteogenic differentiation in a bone morphogenetic protein-dependent manner, it may be used to broaden the sources for cell transplantation and thereby establish more efficient bone regeneration systems. Real-time polymerase chain reaction and western blot were used to detect the expression of SMAD4, a marker of bone formation. Microcomputed tomography and histomorphometric techniques showed that oral treatment with MHA was followed by an increase in the bone mineral density of the lumbar vertebrae in mice. This result also indicates that MHA may directly activate osteopontin gene transcription. In conclusion, MHA seems to enhance the osteogenesis of bone marrow-derived mesenchymal stem cells at least partly via bone morphogenetic protein signalling.
Maohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways
Mol Cell Biochem 2011 Dec;358(1-2):37-44.PMID:21698346DOI:10.1007/s11010-011-0918-y.
Osteoporosis is becoming a more prevalent health problem with the aging of the population around the world. Epimedium koreanum Nakai is one of the most used herbs in East Asia for curing osteoporosis, with its major ingredient, icariin, mostly explored by researchers. In this article, Maohuoside A (MHA), a single isolated compound from the herb, was identified to be more potent than icariin in promoting osteogenesis of rat bone marrow-derived mesenchymal stem cells (rMSCs) (increasing by 16.6, 33.3, and 15.8% on D3, D7, and D11, respectively). Alkaline phosphatase (ALP) assay and calcium content measurement were assigned to quantify the promoted osteogenesis and alizarin red S (ARS) staining was conducted to visualize it. Quantitative real-time PCR (Q-PCR) was assayed to evaluate the mRNA expression of marker genes in osteogenesis and master regulators in BMP pathway. Moreover, PD98059 (PD) and SB203580 (SB), inhibitor of ERK1/2 and p38 MAPK pathway, were administered to assess the involvement of MAPK pathway in the promotion process. In conclusion, MHA pronouncedly enhanced the osteogenesis of rMSC, plausibly via the BMP and MAPK signaling pathways.